FORM D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

OMB APPROVAL

3235-0076

April 30, 2008

OMB NUMBER:

Estimated average burden

hours per response......16.00

Expires:

DE

,	CURITIES PURSUANT TO	S	EC USE ONLY
	ATION D,	Prefix	Serial
	4(6), AND/OR DFFERING EXEMPTION	<u> </u>	
UMPORM EIMTED	FERING EXEMPTION	D.	ATE RECEIVED
Name of Offering (check if this is an amendment and na	me has changed, and indicate change.)	SE	RECEIVED
Convertible Promissory Notes and Warrants		S	
Filing Under (Check box(es) that apply): □ Rule :	504 □ Rule 505 ■ Rule 506 □ Sectio	n 4(6) □ ULOE 🙀 🗀	3 2007
Type of Filing: ■ New Filing □ Amendment		TEAL .	
	A. BASIC IDENTIFICATION DAT	TA Y	186
1. Enter the information requested about the issuer			
Name of Issuer (□ check if this is an amendment and name	has changed, and indicate change.)		
Ivrea Pharmaceuticals, Inc.			
Address of Executive Offices (Number and Street, Ci	ty, State, Zip Code)	Telephone Number (In	cluding Area Code)
216 Ricciuti Drive, Quincy, MA 02169	920050	617-376-2491	
	nber and Street, City, State, Zip Code	Prophone Number (In	cluding Area Code)
different from Executive Offices)	CED O C	0003	
Brief Description of Business:	3EF-U 67	2007 ₇	
Specialty pharmaceuticals company	THOMSO		
Type of Business Organization	FINANCI	AL	- 1
■ corporation □ lin	nited partnership, already formed	□ other (please spe	07076070
□ business trust □ lir	nited partnership, to be formed		07076872
	Month Year		_
Actual or Estimated Date of Incorporation or Organization Jurisdiction of Incorporation or Organization: (Enter two-le	01 05 ■ Actual tter U.S. Postal Service abbreviation for State	☐ Estimated	

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

CN for Canada; FN for other foreign jurisdiction)

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	IFICATION DATA		
 Each executive officer and dire Each general and managing pa 	the issuer has be the power to vot ector of corporat	e or dispose, or direct the e issuers and of corporate	vote or disposition of, 10	% or more of a cartners of partners	lass of equity securities of the issuer; ship issuers; and
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Lynch, Daniel S.					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Ivrea Pharmaceuticals, Inc., 216 Ric	ciuti Drive, Qu	incy, MA 02169			
Check Box(es) that Apply:	□ Promoter	Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Cattaneo, Maurizio					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Ivrea Pharmaceuticals, Inc., 216 Ric	ciuti Drive, Qu	incy, MA 02169			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
SoleRx LLC					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
c/o Ivrea Pharmaceuticals, Inc., 216 Rio	ciuti Drive. Ou	incv. MA 02169			
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)			. =		
Barrett, Peter					
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		
c/o Atlas Venture Fund VI, L.P., 890 W	inter Street Su	ite 320 Waltham MA	02451		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Orlow, Seth					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		-
c/o Ivrea Pharmaceuticals, Inc., 216 Ric	ciuti Drive. Ou	incv. MA 02169			
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				· -	
Garcia, Francisco					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Easton Hunt Capital Partners, L.P.,	767 Third Ave	nue. 7th Floor, New Yor	k. NY 10017		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Greenberg, Myles					
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
c/o CHL Medical Partners II, L.P., 105	Washington F	Blvd Stamford CT 1169	01		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	,				9 9
Silverman, Scott					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Atlas Venture Fund VI, L.P., 890 W	inter Street S.	ijte 320 Waltham MA	02451		
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	□ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Fasten Hunt Carital Bartan I P					
Easton Hunt Capital Partners, L.P. Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
767 Third Avenue, 7th Floor, New York	·	•	•		

		A. BASIC IDENT	IFICATION DATA						
 Enter the information requested for the Each promoter of the issuer, if the Each beneficial owner having the Each executive officer and direct teach general and managing particles. 	the issuer has be he power to vote ctor of corporat	e or dispose, or direct the e issuers and of corporate	vote or disposition of, 10	% or more of a cl urtners of partners	ass of equity securities of the issuer, hip issuers; and				
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual)									
Atlas Venture Fund VI, L.P.									
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)						
890 Winter Street, Suite 320, Waltham,	MA 02451								
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual)	<u> </u>								
CHL Medical Partners II, L.P.									
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)						
1055 Washington Blvd., Stamford, CT 06901									
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	■ Executive Officer	Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual)									
Kelly, Joseph									
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)		-				
c/o Ivrea Pharmaceuticals, Inc., 216 Ric Check Box(es) that Apply:	ciuti Drive, Qu Promoter	Incy, MA 02169 Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual)	LI Fromotet	Benericial Owner	Executive Officer	B Director	General and Hanaging Fautier				
Hensby, Christopher Business or Residence Address	(Mumber and S	Street, City, State, Zip Co	de)						
Business of Residence Address	(Nulliber and)	succi, City, State, Zip Co	uc)						
c/o Ivrea Pharmaceuticals, Inc., 216 Ric	ciuti Drive, Qu	incy, MA 02169							
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual)									
Kobos, Michael									
Business or Residence Address	(Number and S	Street, City, State, Zip Co	de)						
c/o Ivrea Pharmaceuticals, Inc., 216 Ric	ciuti Drive. Ou	incy, MA 02169							
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual)	'								
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)						
			·						
Check Box(es) that Apply:	C Promotor	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual)	□ Promoter	Beneficial Owlier	□ Executive Officer	Director	General and of Wanaging Farmer				
,									
Business or Residence Address	(Number and	Street, City, State, Zip Co	nde)						
Duamess of residence Address	(iranibei alla	ouwi, ony, oute, zip o	July						
GL LD ()dut			··						
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner				
Full Name (Last name first, if individual)									
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)						

	B. INFORMATION ABOUT OFFERING			
			Yes	No
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?			•
	Answer also in Appendix, Column 2, if filing under ULOE.	_		
2.	What is the minimum investment that will be accepted from any individual?	S _	<u>n/a</u> Yes	No
3.	Does the offering permit joint ownership of a single unit?		•	
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.			
Full None	Name (Last name first, if individual) e.			
Busi	ness or Residence Address (Number and Street, City, State, Zip Code)			
Nam	ne of Associated Broker or Dealer			
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers	4.11		
	(Check "All States" or check individual States)		States	
_ [A _ [1 _ [1 _ [1	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] MS] OR] WY]	_ [1D] _ [MO] _ [PA] _ [PR]
Full	name (Last name first, if individual)			
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)			
Nam	ne of Associated Broker or Dealer			
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers			
	(Check "All States" or check individual States)	All	States	
_ []	MT] _[NE] _[NV] _[NH] _[NJ] _[NM] _[NY] _[NC] _[ND] _[OH] _[OK]	-	[HI] [MS] [OR] [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	Name (Last name first, if individual)			·
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)			
Nam	ne of Associated Broker or Dealer			
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers			
	(Check "All States" or check individual States)	All	States	
_ [] _ [] _ []	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_	[HI] [MS] [OR] [WY]	_ [ID] _ [MO] _ [PA] _ [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box pand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	s	s
	Equity	\$	\$
	□ Common □ Preferred		
	Convertible Securities (including warrants)	\$ 2,500,000	\$ 2,500,000
	Partnership Interests	s	S
	Other (Specify Warrants)	\$ <u> </u>	\$
	Total	\$_2,500,000	\$ 2,500,000
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	6	\$ 2,500,000
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		S
	Answer also in Appendix, Column 4, if filing under ULOE		<u></u>
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C — Question 1. Type of offering Rule 505	Type of Security	Dollar Amount Sold
	Regulation A		s
	Rule 504		s
	Total		.
	10121		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		s
	Printing and Engraving Costs		s
	Legal Fees	•	\$ 20,000
	Accounting Fees		\$
	Engineering Fees.		<u> </u>
	Sales Commissions (specify finders' fees separately)	0	s
			·
	Other Expenses (identify)		3
	Total	•	\$ <u>20,000</u>

	b. Enter the difference between the aggregate offer	ing price given in response to Part	C - Question			
	I and total expenses furnished in response to Part C "adjusted gross proceeds to the issuer."	- Question 4.a. This difference is	s the		5	2,480,000
5.	Indicate below the amount of the adjusted gross profor each of the purposes shown. If the amount for a and check the box to the left of the estimate. The to adjusted gross proceeds to the issuer set forth in res	ny purpose is not known, furnish a tal of the payments listed must eq	an estimate ual the			
				Payments to Officers, Directors, & Affiliates		Payments 1 Others
	Salaries and fccs.	***************************************	a	\$	۵	\$
	Purchase of real estate	11111111111111111111111111111111111111		s	0	\$
	Purchase, rental or leasing and installation of machi-	nery and equipment	Ġ	\$	0	\$
	Construction or leasing of plant buildings and facilit	ies	٥	s	O	\$
	Adoptisition of other business (including the value of that may be used in exchange for the assets or secur					
	merger)			\$		5
	Repayment of indebtedness	[/4;5	o o	S		\$
	Working capital			\$	-	\$ 2,480,000
	Other (specify):	·	_ 0	S		\$
				\$	٥	\$
	Column Totals	····	•	\$		\$ <u>2,480,000</u>
	Total Payments Listed (column totals added)	***************************************		■ S <u>2</u> .	480,000	_
	the state of the s					
			. 771		_	
		D. FEDERAL SIGNA	ATURE			
		D. FEDERAL SIGNA	ATURE			
un	suer has duly caused this notice to be signed by the detaking by the issuer to furnish to the U.S. Securiti	undersigned duly authorized persons and Exclusive Commission, up	on. If this notice is	s filed under Rule 505, the of its staff, the information	following s	signature constitu
un	sucr has duly caused this notice to be signed by the	undersigned duly authorized persons and Exclusive Commission, up	on. If this notice is	s filed under Rule 505, the of its staff, the information	following s	signature constitu by the issuer to
un n-c	sucr has duly caused this notice to be signed by the dertaking by the issuer to furnish to the U.S. Securitic ceredited investor pursuant to paragraph (b)(2) of Ru	undersigned duly authorized persons and Exchange Commission, up the 502.	on. If this notice is on written request	of its staff, the information	following s	signature constitu by the issuer to
un n-c	sucr has duly caused this notice to be signed by the dertaking by the issuer to furnish to the U.S. Securitic ceredited investor pursuant to paragraph (b)(2) of Ru	undersigned duly authorized persons and Exchange Commission, upple 502.	on. If this notice is	of its staff, the information	following s	signature constitute to the issuer to
un n-c	sucr has duly caused this notice to be signed by the dertaking by the issuer to furnish to the U.S. Securities ceredited investor pursuant to paragraph (b)(2) of Ru (Print or Type)	undersigned duly authorized persons and Exchange Commission, upple 502.	on. If this notice is on written request	of its staff, the information	following s	signature constitute to the issuer to

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)